CorMedix维持2026财年营收预期,上调调整后EBITDA指引

美股速递
Aug 13

CorMedix Inc.公布了其2026财年的业绩展望:该公司的营收指引保持不变,依然锁定在3.25亿至3.45亿美元之间。然而,在盈利能力方面,这家企业表现出了更强的信心——它已将2026财年调整后EBITDA(税息折旧及摊销前利润)预期从先前的水平上调至1.25亿至1.4亿美元。这一调整,反映出管理层对运营效率与成本控制的乐观预期。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10